Arkolith/Insider Trading/LXEO/Form 4

Townsend Richard Nolan

Chief Executive Officer, DirectorLexeo Therapeutics, Inc. (LXEO) · full profile →Form 4 · filed Dec 12, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$21K
Net Open-Market Flow
-$21K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 10, 2024Option exercise(M)3K$2.33$6K123K
Dec 10, 2024Sell(S)3K$8.20$21K121K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 10, 2024Option exercise(M)3K—$0119K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-029143) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML